Second quarter results met expectations with strong volume growth from improved mortality, offset by lower commercial mix and phosphate binder revenue. Full-year guidance is reaffirmed, with continued investment in clinical innovation and capital allocation discipline.Based on DaVita Inc. [DVA] Q2…
Second quarter results met expectations with strong volume growth from improved mortality and operational execution. Revenue per treatment declined sequentially due to mix and policy changes, but full-year guidance was reaffirmed. Expanded HD therapies and capital initiatives support future growth…
DaVita Inc. reported results for the quarter ended 2026 with revenue of $3.55B, net income of $265.4M and diluted EPS of $4.02, versus $3.38B, $199.34M and $2.58, respectively, in the prior-year quarter.Financial Highlights¹ Reported as “Total revenues”. ² Reported as “Net income attributable to Da…
Q2 2026 saw revenue rise 5.2% year-over-year to $3.55 billion and net income attributable to shareholders increase to $265 million, with strong growth in both U.S. dialysis and ancillary services. Free cash flow and operating income improved, while labor and regulatory pressures remain key risks.Or…
Q2 2026 saw revenues of $3.554 billion, operating income of $579 million, and diluted EPS of $4.02, with strong cash flow and continued share repurchases. Guidance for 2026 remains robust, and the company maintains a healthy leverage ratio while navigating reimbursement and regulatory risks.Origina…
Dialysis provider DaVita Inc. NYSE:DVAwill be reporting earnings this Tuesday afternoon. Here’s what you need to know.DaVita beat analysts’ revenue expectations last quarter, reporting revenues of $3.42 billion, up 6% year on year. It was a very strong quarter for the company, with a beat of analys…
DENVER, July 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 4, 2026, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.This call i…
By Andrew BaryBerkshire investment manager Ted Weschler appears to be having a strong 2026 after some tougher years because of big gains in two stocks — DaVita and Sirius XM Holdings.Weschler is responsible for running about 6% of Berkshire's equity portfolio of more than $300 billion under the ove…
DaVita Inc. DVA, a well-known kidney care services provider, plays a central role in the dialysis ecosystem by providing comprehensive kidney care services for patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). The company operates an extensive network of outpatient dia…
